Literature DB >> 33593479

Current Treatment for Benign Prostatic Hyperplasia.

Arkadiusz Miernik1, Christian Gratzke.   

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) is characterized by the occurrence of.disorders of urine storage and bladder emptying. Most men over the age of 60 years are affected to some degree.
METHODS: A selective literature search with additional scrutiny of guidelines and meta-analyses.
RESULTS: The management of patients with BPH is complex. Emptying and retention disorders can be treated by various pharmacological and surgical means. Transurethral resection of the prostate (TURP) has long been considered the gold standard for operative treatment. Transurethral enucleation procedures show a better risk profile in some uses, however, and have, above all, largely displaced suprapubic prostatectomy. Numerous innovative treatment options have been developed in recent years, but their long-term effects remain to be determined. These treatment techniques can nevertheless be used in individual cases after thorough discussion with the patient.
CONCLUSION: The care of patients with BPH should be interdisciplinary. The efficacy and safety of many new developments in the area of pharmacological and minimally invasive treatment remain to be demonstrated in randomized trials.

Entities:  

Mesh:

Year:  2020        PMID: 33593479      PMCID: PMC8021971          DOI: 10.3238/arztebl.2020.0843

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  92 in total

1.  Efficacy and safety of aquablation of the prostate for patients with symptomatic benign prostatic enlargement: a systematic review.

Authors:  Rodrigo Suarez-Ibarrola; Thorsten Bach; Simon Hein; Andrea Cocci; Giorgio Ivan Russo; Thomas R W Herrmann; Christian Gratzke; Arkadiusz Miernik
Journal:  World J Urol       Date:  2019-09-26       Impact factor: 4.226

2.  Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting.

Authors:  N R Netto; M L de Lima; M R Netto; C A D'Ancona
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

3.  Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial.

Authors:  Mihir Desai; Mo Bidair; Kevin C Zorn; Andrew Trainer; Andrew Arther; Eugene Kramolowsky; Leo Doumanian; Dean Elterman; Ronald P Kaufman; James Lingeman; Amy Krambeck; Gregg Eure; Gopal Badlani; Mark Plante; Edward Uchio; Greg Gin; Larry Goldenberg; Ryan Paterson; Alan So; Mitch Humphreys; Claus Roehrborn; Steven Kaplan; Jay Motola; Naeem Bhojani
Journal:  BJU Int       Date:  2019-03-29       Impact factor: 5.588

4.  Risk factors for intraoperative floppy iris syndrome: a meta-analysis.

Authors:  Irini P Chatziralli; Theodoros N Sergentanis
Journal:  Ophthalmology       Date:  2010-12-18       Impact factor: 12.079

5.  Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study.

Authors:  Claus G Roehrborn; Jack Barkin; Steven N Gange; Neal D Shore; Jonathan L Giddens; Damien M Bolton; Barrett E Cowan; Anthony L Cantwell; Kevin T McVary; Alexis E Te; Shahram S Gholami; William G Moseley; Peter T Chin; William T Dowling; Sheldon J Freedman; Peter F Incze; K Scott Coffield; Sean Herron; Prem Rashid; Daniel B Rukstalis
Journal:  Can J Urol       Date:  2017-06       Impact factor: 1.344

6.  Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.

Authors:  Claus G Roehrborn
Journal:  BJU Int       Date:  2006-04       Impact factor: 5.588

7.  Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

Authors:  Victor W Nitti; Stephen Auerbach; Nancy Martin; Alaina Calhoun; Misun Lee; Sender Herschorn
Journal:  J Urol       Date:  2012-10-16       Impact factor: 7.450

Review 8.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

9.  Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy.

Authors:  R M Anikwe
Journal:  Int Surg       Date:  1976-08

Review 10.  Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience.

Authors:  Sara J Allison; William Gibson
Journal:  Ther Adv Urol       Date:  2018-09-26
View more
  4 in total

Review 1.  [Learning from coding data-surgical treatment of benign prostatic syndrome : Big data for BPS].

Authors:  Nadine Binder; J Franz; A Sigle; C Gratzke; A Miernik
Journal:  Urologe A       Date:  2021-12-23       Impact factor: 0.639

Review 2.  Laser enucleation of the prostate in men with very large glands ≥175 ml: A systematic review.

Authors:  Mehmet Yilmaz; Mustafa Karaaslan; Halil Cagri Aybal; Maximilian Ferry von Bargen; Senol Tonyali; Tuncay Toprak; Christian Gratzke; Arkadiusz Miernik
Journal:  Ann Med Surg (Lond)       Date:  2022-07-31

3.  Risk Factors of Urinary Pathogenic Bacteria Infection after Benign Prostatic Hyperplasia Surgery and Curative Effect Analysis of Shuangdong Capsule Intervention.

Authors:  Bing Xu; Ming Liu; Yonghui Liu; Jianhong Zuo
Journal:  Emerg Med Int       Date:  2022-09-08       Impact factor: 1.621

4.  Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects.

Authors:  Chen Zhu; Juan Wu; Yixian Wu; Wen Guo; Jing Lu; Wenfang Zhu; Xiaona Li; Nianzhen Xu; Qun Zhang
Journal:  Front Nutr       Date:  2022-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.